# DESCRIPTION

## TECHNICAL FIELD OF INVENTION

- relate to polypeptide fragments of PA subunit
- relate to crystals of polypeptide fragments
- relate to computational methods for compound screening

## BACKGROUND OF THE INVENTION

- introduce Influenza
- describe Influenza epidemics
- describe limitations of vaccination
- introduce antiviral medication
- describe neuraminidase inhibitors
- describe amantadine and rimantadine
- describe ribavirin
- describe Orthomyxoviridae family
- describe RNA-dependent RNA polymerase
- describe cap-snatching mechanism
- describe PB2 subunit
- describe PB1 subunit
- describe PA subunit
- describe endonucleolytic activity
- describe attempts to target polymerase subunits
- describe attempts to target viral transcription
- describe attempts to target endonuclease activity
- describe PA subunit as antiviral drug target
- describe recent findings on PA subunit
- describe achievement of present inventors

## SUMMARY OF THE INVENTION

- introduce polypeptide fragment of PA subunit
- introduce isolated polynucleotide
- introduce recombinant vector
- introduce recombinant host cell
- describe method for identifying compounds
- describe computational method
- describe in vitro method
- introduce compound modulating endonuclease activity
- introduce pharmaceutical composition
- introduce antibody
- describe use of compound or composition
- describe use of antibody
- describe specific compounds

## DETAILED DESCRIPTION OF THE INVENTION

- disclaim limitations of invention
- define terminology
- describe elements of invention
- explain combinations of elements
- define preferred terms
- reference conventional methods
- clarify language usage

### Definitions

- define polypeptide fragment
- define protein
- define peptide
- define peptoid
- define corresponding residues
- explain alignment tools
- define best sequence alignment
- define region of best sequence alignment
- introduce RNA-dependent RNA polymerase PA subunit
- define PA subunit variant
- explain sequence similarity
- explain sequence identity
- define PA polypeptide fragment
- define PA polypeptide fragment variants
- explain additional amino acids
- define alignment score
- explain endonuclease active site
- define PA polypeptide fragment variants with serine
- define PA-Nter
- define PA-Nter mutant
- explain sequence similarity searching tools
- define soluble
- explain solubility test
- define purified
- explain purification methods
- define associate
- explain endonuclease activity
- explain endonucleolytic activity
- define single stranded
- define nucleotide
- define isolated polynucleotide
- define recombinant vector
- define expression vector
- define cloning vector
- define recombinant host cell
- explain types of host cells
- define crystal
- define unit cell
- define space group
- define structure coordinates
- define root mean square deviation
- define constructing a computer model
- define fitting program operation
- define test compound
- define small molecules
- define compound which modulates endonucleolytic activity
- define compound which decreases endonucleolytic activity
- define high-throughput setting
- define antibody
- define antigen-binding portions
- define pharmaceutically acceptable salt
- define acid addition salts
- define alkali metal salts
- define alkaline earth metal salts
- define salts formed with organic ligands
- define pharmaceutically acceptable excipient
- define carriers
- define binders
- define lubricants
- define thickeners
- define surface active agents
- define preservatives
- define emulsifiers
- define buffers

### DETAILED DESCRIPTION

- introduce PA polypeptide fragment
- describe endonuclease activity
- motivate crystallization
- define polypeptide fragment
- specify preferred embodiments
- describe solubility
- determine minimal length
- specify endonuclease activity
- describe crystallization conditions
- specify protein concentration
- describe buffer system
- specify pH range
- describe precipitant solution
- specify salt concentrations
- describe co-crystallization
- specify compound concentrations
- describe crystallization medium
- specify preferred crystallization conditions
- describe co-crystallization with modulators
- specify preferred co-crystallization conditions
- provide examples of co-crystallization
- describe crystallization methods
- list crystallization conditions
- explain microseeding
- describe obtaining structure coordinates
- interpret structure coordinates
- describe utility of structure coordinates
- specify preferred amino terminal PA fragment
- describe purification of polypeptide fragment
- specify preferred purification extent
- describe binding to divalent cations
- specify preferred divalent cations
- describe coordination of divalent cations
- specify preferred N-terminus and C-terminus
- describe variant with amino acid serine at position 186
- describe variant with glycine replacement
- describe variant with glycine replacement and linker
- describe further variant with glycine replacement
- describe further variant with glycine replacement and linker
- specify preferred amino acid sequence
- describe polypeptide fragment with structure defined by FIG. 1
- describe polypeptide fragment with structure defined by FIG. 2-5, 15 or 16
- specify preferred crystal structure
- describe crystal structure with space group and unit cell dimensions
- specify preferred X-ray diffraction resolution
- list examples of X-ray diffraction resolutions
- conclude crystal structure description
- provide isolated polynucleotide
- code for PA polypeptide fragment
- code for PA polypeptide fragment variant
- code for PA polypeptide fragment variant
- code for PA polypeptide fragment variant
- obtain isolated nucleotide fragments
- isolate RNA from infected cells
- generate cDNA using RT-PCR
- amplify fragments using PCR
- derive isolated polynucleotides from SEQ ID NO: 1
- provide recombinant vector
- incorporate polynucleotide sequence into vector
- include regulatory sequences in vector
- include epitope-, peptide-, or protein-tags in vector
- cleave off tags using protease
- include functional sequences for secretion
- provide recombinant host cell
- introduce isolated polynucleotide or vector into host cell
- express polynucleotide fragment of interest
- purify polypeptide fragments
- identify compounds modulating endonuclease activity
- construct computer model of active site
- select potential modulating compound
- evaluate association between compound and active site
- quantify ability of compound to associate with active site
- describe molecular design techniques
- identify compounds modulating endonucleolytic activity
- generate structure coordinates of PA subunit
- convert structure coordinates into 3D shape
- screen chemical entities for modulating activity
- visually inspect 3D computer model of active site
- position fragments or compounds in active site
- dock compounds within active site
- perform energy minimization and molecular dynamics
- select suitable compounds or fragments
- design or assemble compounds into single compound
- perform manual model building
- connect individual compounds or fragments
- computationally screen small molecule databases
- judge quality of fit by shape complementarity
- judge quality of fit by estimated interaction energy
- design modulator de novo based on 3D structure
- optimize compound deformation energy
- evaluate electrostatic interaction
- make conservative substitutions to improve binding
- analyze substituted compounds for efficiency of fit
- describe endonucleolytically active site of PA subunit
- specify amino acids of active site
- provide embodiments of active site
- list amino acids corresponding to active site
- define active site
- specify amino acids
- specify amino acids
- specify amino acids
- specify amino acids
- specify amino acids
- specify amino acids
- specify amino acids
- specify amino acids
- specify amino acids
- specify amino acids
- specify amino acids
- specify amino acids
- define active site
- define active site
- define active site
- define active site
- define active site
- define active site
- define active site
- define active site
- define active site
- define active site
- define active site
- define active site
- define active site
- define active site
- define active site
- define active site
- define active site
- define active site
- define active site
- define active site
- define active site
- define active site
- define active site
- define active site
- define active site
- define active site
- define active site
- define active site
- identify required amino acids
- describe compound binding
- discuss importance of 3D knowledge
- outline design of new compounds
- describe computer modeling
- indicate binding of compound
- synthesize and formulate compound
- test ability to modulate endonucleolytic activity
- describe testing in vitro or in vivo
- outline further step of testing
- define Influenza A 2009 pandemic H1N1 PA subunit polypeptide fragment
- describe endonuclease activity
- introduce compound modulating endonuclease activity
- specify compound binding to active site
- describe active site structure
- list amino acids in active site
- describe method for identifying compound
- introduce test compound
- describe reaction conditions
- analyze substrate degradation
- introduce alternative test method
- describe labeled substrate molecule
- specify compound types
- exclude specific compounds
- describe in vitro method for identifying compounds
- introduce pull-down assay
- describe ELISA-based experiment
- introduce peptide array
- describe co-immunoprecipitation
- introduce directly labeled test compounds
- describe high-throughput screening
- specify test compound libraries
- introduce in vivo testing
- describe viral plaque formation
- specify small molecule inhibitors
- describe peptide or protein libraries
- formulate compound with excipients
- introduce compound modulating endonuclease activity
- specify compound binding to active site
- describe compound modulating endonuclease activity
- specify compound binding to active site
- introduce compound modulating endonuclease activity
- specify compound binding to active site
- describe compound modulating endonuclease activity
- specify compound binding to active site
- introduce compound modulating endonuclease activity
- specify compound binding to active site
- describe compound modulating endonuclease activity
- specify compound binding to active site
- introduce compound modulating endonuclease activity
- specify compound binding to active site
- describe compound modulating endonuclease activity
- specify compound binding to active site
- introduce compound modulating endonuclease activity
- specify compound binding to active site
- describe compound modulating endonuclease activity
- specify compound binding to active site
- describe compound modulation of endonuclease activity
- specify preferred embodiments of compound
- exclude specific compounds from invention
- introduce pharmaceutical composition
- describe pharmaceutical composition components
- specify compound's ability to modulate endonuclease activity
- describe production of pharmaceutical composition
- discuss computational modeling and screening
- introduce optimization of pharmacology
- describe computer programs for pharmacophore selection
- formulate pharmaceutical composition
- specify solid administration forms
- list excipients for solid administration forms
- describe aqueous suspensions and solutions
- introduce release rate modifiers
- describe fast dispersing or dissolving dosage formulations
- specify ingredients for fast dispersing or dissolving dosage formulations
- prepare suppositories
- prepare pharmaceutical composition for parenteral administration
- prepare pharmaceutical composition for intranasal administration
- describe aerosol spray delivery
- define antibody
- specify antibody variant
- describe preferred embodiment
- detail polypeptide fragment recognition
- specify epitope length
- list preferred epitopes
- describe antibody production
- detail polyclonal antibody generation
- describe monoclonal antibody generation
- explain hybridoma selection
- describe antibody characteristics
- relate to pharmaceutical composition
- specify disease treatment
- describe compound modulation
- detail endonuclease activity
- specify compound identification
- relate to pharmaceutical composition production
- describe disease prevention
- specify compound treatment
- detail disease conditions
- relate to specific compounds
- describe compound administration
- detail pharmaceutical composition formulation
- specify unit dosage form
- describe active component quantity
- detail initial dosage
- specify daily dose range
- describe dosage variation
- relate to invention modifications
- describe invention scope

### EXAMPLES

- clone and express PA-Nter protein
- engineer PA-Nter mutant with improved crystallization properties
- purify PA-Nter protein
- crystallize PA-Nter protein with and without compounds/ligands
- describe crystallization conditions for native crystals and co-crystals
- describe cryo-protection methods for crystals
- list compounds used for co-crystallization
- describe crystallization results
- show crystal structure of PA-Nter with rUMP

### 2. Results

- summarize PA H1N1 polypeptide fragment or variant generation and crystallization
- describe crystallization properties of PA H1N1 polypeptide fragment or variant
- describe structure of PA H1N1 polypeptide fragment or variant with and without compounds/ligands
- describe H1N1 PA native structure
- describe EMBL-R05-3-bound structure
- compare native and EMBL-R05-3-bound structures
- describe EMBL-R05-3-bound structure with different configuration
- describe EMBL-R05-2-bound structure
- describe rUMP-bound structure
- describe co-crystallization trials with rUMP
- compare rUMP-bound structure with previously published structure
- describe EMBL-R05-1-bound structure
- describe EGCG-bound structure
- describe EGCG binding mode
- superpose all diketo inhibitor compounds and EGCG
- describe divalent cation binding in native structure
- describe divalent cation binding in other structures
- show structural co-ordinates of native H1N1 PA endonuclease domain
- show structural co-ordinates of H1N1 PA endonuclease domain with EMBL-R05-3
- show structural co-ordinates of H1N1 PA endonuclease domain with EMBL-R05-2
- show structural co-ordinates of H1N1 PA endonuclease domain with rUMP
- show structural co-ordinates of H1N1 PA endonuclease domain with EMBL-R05-1
- show structural co-ordinates of H1N1 PA endonuclease domain with EGCG
- illustrate endonuclease active site with bound compounds/ligands

